

Dink
B1

I claim:

1. A composition for the nasal administration of a drug to a patient comprising
a drug in a dry powder form having an average particle size of between
10 and 20 microns, in a dosage formulation suitable for administration to the
nasal region.

2. The composition of claim 1 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

3. The composition of claim 2 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

4. The composition of claim 1 wherein the drug is formulated in a polymeric carrier.

5. The composition of claim 1 wherein the drug is formulated in a diketopiperazine formulation.

6. The composition of claim 1 wherein the dry powder formulation consists essentially of drug.

7. A drug delivery device for nasal administration comprising
a drug in a dry powder form having an average particle size of between
10 and 20 microns, in a dosage formulation for administration to the nasal
region, and

a device for delivering a measured dose of the drug to the nasal mucosa.

8. The device of claim 7 wherein the device is a nasal insufflator.

9. The device of claim 7 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

10. The device of claim 7 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

11. The device of claim 7 wherein the drug is formulated in a polymeric carrier.

12. The device of claim 7 wherein the drug is formulated in a

*fwl
fb 3*

diketopiperazine formulation.

13. The device of claim 7 wherein the dry powder formulation consists essentially of drug.

14. A method of administering a drug to the nasal region of a patient in need thereof, comprising nasally administering a dry powder form of a drug having an average particle size of between 10 and 20 microns, in a dosage formulation suitable for nasal administration.

15. The method of claim 14 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

16. The method of claim 14 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

17. The method of claim 14 wherein the drug is formulated in a polymeric carrier.

18. The method of claim 14 wherein the drug is formulated in a diketopiperazine formulation.

19. The method of claim 14 wherein the dry powder formulation consists essentially of drug.